One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists

One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists

Saved in:

Bibliographic Details
Main Author:	Hirotaka Watada
Format:	Article
Language:	English
Published:	Wiley 2025-02-01
Series:	Journal of Diabetes Investigation
Subjects:	Anti‐inflammation Glucagon‐like peptide‐1 receptor agonists T cells
Online Access:	https://doi.org/10.1111/jdi.14346
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Nephroprotective potential of glucagon-like peptide-1 receptor agonists
by: Minara S. Shamkhalova, et al.
Published: (2020-04-01)

Meta-analysis of the efficacy of glucagon-like peptide-1 receptor agonists in the treatment of diabetic nephropathy
by: Ze-jin Liao, et al.
Published: (2024-12-01)

Association of Glucagon‐Like Peptide Agonist Therapy With Dietary Patterns in a Cross‐Sectional Cohort
by: Eric J. Brandt, et al.
Published: (2025-06-01)

Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
by: Richard J. MacIsaac, et al.
Published: (2024-10-01)

Glucagon-like peptide-1 receptor agonists: a review from a cardiovascular perspective
by: Yosra Turkistani
Published: (2025-04-01)

Research progress on mechanisms of glucagon-like peptide-1 receptor agonists in diabetic retinopathy
by: HE Cuihuan, SHI Derong, SUN Dandan, LI Yurui, XIA Guanghao
Published: (2025-02-01)

Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
by: Gagik R. Galstyan, et al.
Published: (2017-10-01)

A comparison of Glucagon-like peptide-1 receptor agonists on weight change, side effects, and quality of life in Kuwait
by: Saleh Alali, et al.
Published: (2025-05-01)

Health Disparity Clusters of Off Label Prescriptions for Glucagon-Like Peptide 1 Receptor Agonists
by: Kateri J. Spinelli, et al.
Published: (2025-06-01)

Impact of Perioperative Glucagon-Like Peptide-1 Receptor Agonists on Postoperative Outcomes Following Carpal Tunnel Release
by: Nicholas C. Bank, MD, et al.
Published: (2025-07-01)

Glucagon-like peptide-1 receptor agonist-induced cholecystitis and cholelithiasis: a real-world pharmacovigilance analysis using the FAERS database
by: Chao Tao, et al.
Published: (2025-07-01)

Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence
by: Anqi Lin, et al.
Published: (2025-03-01)

Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges
by: Zhi Dong Zhou, et al.
Published: (2025-06-01)

Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Venous Thromboembolism: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
by: Yiwen Liu, et al.
Published: (2025-05-01)

Glucagon-like peptide-1 receptor agonists, inflammation, and kidney diseases: evidence from Mendelian randomization
by: Yu-Xuan Yao, et al.
Published: (2025-12-01)

Therapeutic strategies, consequences and prospects of glucagon-like peptide-1 agonists
by: N.M. Bobok
Published: (2025-05-01)

Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study
by: Brittany Johnson, et al.
Published: (2025-04-01)

Physiology and pharmacology of glucagon-like peptide-1 receptor
by: D. V. Kurkin, et al.
Published: (2024-01-01)

Investigation of potential relationship between glucagon-like peptide 1 receptor agonists with suicide/self-injury: disproportionality analysis using WHO-VigiBase
by: Ye Young Kim, et al.
Published: (2024-12-01)

Safety and efficacy of glucagon-like peptide-1 receptor agonists in patients with obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trials
by: Obieda Altobaishat, et al.
Published: (2025-12-01)

Efficacy and Safety of Glucagon‐Like Peptide‐1 Agonists for Psychiatric Symptoms: A Systematic Review
by: Shakila Meshkat, et al.
Published: (2025-07-01)

Efficacy and safety of glucagon-like peptide-1 receptor agonists therapy initiation in patients with type 2 diabetes hospitalized with coronavirus infection
by: T. N. Markova, et al.
Published: (2023-12-01)

Glucagon-Like Peptide-1 and Hypothalamic Regulation of Satiation: Cognitive and Neural Insights from Human and Animal Studies
by: Joon Seok Park, et al.
Published: (2025-05-01)

Glucagon-like peptide-1 receptor agonist use is associated with reduced risk of out-of-hospital cardiac arrest in women with type 2 diabetes: A nationwide nested case-control study
by: Talip E. Eroglu, et al.
Published: (2024-12-01)

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and cardiometabolic protection: historical development and future challenges
by: Francisco Westermeier, et al.
Published: (2025-01-01)

Comparative Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists to Dipeptidyl Peptidase 4 Inhibitors in Patients With Heart Failure and Type 2 Diabetes
by: Takefumi Kishimori, et al.
Published: (2025-02-01)

Could Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists Play a Role in Gout Treatment?
by: Dan Kaufmann, et al.
Published: (2025-06-01)

The advisory board resolution on the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes
by: M. B. Antsiferov, et al.
Published: (2023-05-01)

Diet quality and nutrient distribution while using glucagon-like-peptide-1 receptor agonist: A secondary cross-sectional analysis
by: Brittany V.B. Johnson, et al.
Published: (2025-12-01)

Association of glucagon-like peptide-1 receptor agonists with atrial fibrillation, cardiac arrest, and ventricular fibrillation: Casual evidence from a drug target Mendelian randomization
by: Xinyi Zhang, et al.
Published: (2025-05-01)

Glucagon-like peptide-1 receptor agonists in liver transplant recipients with diabetes: changes in glucose control and cardiometabolic risk factors
by: Valeria Grancini, et al.
Published: (2025-05-01)

Use of Glucagon-Like Peptide-1 Receptor Agonists Does Not Increase the Risk of Cancer in Patients with Type 2 Diabetes Mellitus
by: Mijin Kim, et al.
Published: (2025-01-01)

Impact of GLP-1 Receptor Agonists on Perceived Eating Behaviors in Response to Stimuli
by: Cheney C, et al.
Published: (2025-05-01)

The role of glucagon-like peptide-1 receptor agonists in the correction of immune and metabolic disorders in women with reproductive dysfunction
by: N. D. Kozhukhov, et al.
Published: (2020-04-01)

What Are the Experiences, Views and Perceptions of Patients, Carers and Clinicians of Glucagon‐like Peptide‐1 Receptor Agonists (GLP‐1 RAs)? A Scoping Review
by: Sam Febrey, et al.
Published: (2025-04-01)

Comparison of Effects of Glucagon-Like Peptide-1 Receptor Agonists Compared to Long-Acting Insulin, Added to Oral Anti-Diabetic Agents on Self-Management Behaviors, Anxiety, and Sleep Quality in Patients with Type 2 Diabetes
by: Song X, et al.
Published: (2025-03-01)

Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
by: Nina A. Petunina, et al.
Published: (2018-09-01)

Enhanced renoprotective effects of combined glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Real‐world evidence
by: Jian‐Yu Jhu, et al.
Published: (2025-02-01)

Efficacy and safety of glucagon-like peptide-1 receptor agonists in the elderly versus non-elderly patients with type 2 diabetes mellitus: insights from a systematic review
by: Yao Wang, et al.
Published: (2024-06-01)

Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers
by: Caroline Holm Nørgaard, et al.
Published: (2022-01-01)